



## Clinical trial results:

### An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents with Active Crohn's Disease Who Completed C87035 or Were Terminated from C87035 when the Study Was Stopped by UCB

#### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2017-005025-20   |
| Trial protocol           | Outside EU/EEA   |
| Global end of trial date | 27 November 2017 |

#### Results information

|                                |  |
|--------------------------------|--|
| Result version number          | v2 (current)   |
| This version publication date  | 08 October 2020  |
| First version publication date | 10 June 2018   |
| Version creation reason        | <ul style="list-style-type: none"><li>• Correction of full data set Alignment with final posting on ClinicalTrials.gov after NIH review.</li></ul> |

#### Trial information

##### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | CR0012 |
|-----------------------|--------|

##### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

#### Sponsors

|                              |   |
|------------------------------|---|
| Sponsor organisation name    | UCB BIOSCIENCES, INC.   |
| Sponsor organisation address | 8010 Arco Corporate Drive, Raleigh, United States, NC 27617                       |
| Public contact               | Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com |
| Scientific contact           | Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com |

Notes:

#### Paediatric regulatory details

|  |     |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No  |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No  |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

|  |                  |
|--|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 16 February 2018 |
| Is this the analysis of the primary completion data? | No               |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 27 November 2017 |
| Was the trial ended prematurely?                     | No               |

Notes:

## General information about the trial

Main objective of the trial:

To assess the longterm safety and tolerability of certolizumab pegol (CZP) in children and adolescents with moderately to severely active Crohn's disease (CD) who completed or were terminated from C87035 (NCT00899678) when the study was stopped by UCB; and to assess the longterm efficacy, pharmacokinetics (PK), and immunogenicity of CZP treatment on this population.

Protection of trial subjects:

During the conduct of the study all subjects were closely monitored.

Background therapy:

Not applicable

Evidence for comparator:

Not applicable

|   |                |
|---|----------------|
| Actual start date of recruitment                          | 06 August 2010 |
| Long term follow-up planned                               | No             |
| Independent data monitoring committee (IDMC) involvement? | Yes            |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                   |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | Australia: 1      |
| Country: Number of subjects enrolled | Canada: 3         |
| Country: Number of subjects enrolled | United States: 12 |
| Worldwide total number of subjects   | 16                |
| EEA total number of subjects         | 0                 |

Notes:

### Subjects enrolled per age group

|   |    |
|---|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 0  |
| Children (2-11 years)                     | 4  |
| Adolescents (12-17 years)                 | 11 |
| Adults (18-64 years)                      | 1  |

|                     |   |
|---------------------|---|
| From 65 to 84 years | 0 |
| 85 years and over   | 0 |

## Subject disposition

### Recruitment

Recruitment details:

The study started to enroll patients in August 2010 and concluded in November 2017.

### Pre-assignment

Screening details:

The study included an Open Label treatment period, having 16 subjects enrolled in the Safety Set (SS) shown in the Participant Flow.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Not blinded                    |

### Arms

|                              |  |
|------------------------------|--|
| Are arms mutually exclusive? | Yes  |
| <b>Arm title</b>             | Certolizumab pegol: low-dose group (weight adjusted) |

Arm description:

200 mg administered subcutaneously every 4 weeks for subjects  $\geq 40$  kg or 100 mg for subjects 20 to  $< 40$  kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

|  |                        |
|--|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | Certolizumab pegol     |
| Investigational medicinal product code | CZP                    |
| Other name                             | Cimzia                 |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Subcutaneous use       |

Dosage and administration details:

200 or 400 mg administered subcutaneously every 4 weeks for subjects  $\geq 40$  kg; 100 or 200 mg for subjects 20 to  $< 40$  kg

|                  |   |
|------------------|---|
| <b>Arm title</b> | Certolizumab pegol: high-dose group (weight adjusted) |
|------------------|---|

Arm description:

400 mg administered subcutaneously every 4 weeks for subjects  $\geq 40$  kg or 200 mg for subjects 20 to  $< 40$  kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

|  |                        |
|--|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | Certolizumab pegol     |
| Investigational medicinal product code | CZP                    |
| Other name                             | Cimzia                 |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Subcutaneous use       |

Dosage and administration details:

200 or 400 mg administered subcutaneously every 4 weeks for subjects  $\geq 40$  kg; 100 or 200 mg for subjects 20 to  $< 40$  kg

| Number of subjects in period 1 | Certolizumab pegol:<br>low-dose group<br>(weight adjusted) | Certolizumab pegol:<br>high-dose group<br>(weight adjusted) |
|--------------------------------|--|---|
| Started                        | 4  | 12  |
| Re-Induction                   | 0 <sup>[1]</sup>   | 2 <sup>[2]</sup>  |
| Completed                      | 3  | 3   |
| Not completed                  | 1  | 9   |
| Consent withdrawn by subject   | -  | 2   |
| Administrative decision        | 1  | -   |
| Adverse event, non-fatal       | -  | 3   |
| Lack of efficacy               | -  | 2   |
| PI discretion                  | -  | 2   |

---

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Number of participants at the milestones reflects those who had not been previously re-induced in C87035 and were eligible for 1 reinduction due to the loss of response in CR0012.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Number of participants at the milestones reflects those who had not been previously re-induced in C87035 and were eligible for 1 reinduction due to the loss of response in CR0012.

## Baseline characteristics

### Reporting groups

|                       |  |
|-----------------------|--|
| Reporting group title | Certolizumab pegol: low-dose group (weight adjusted) |
|-----------------------|--|

Reporting group description:

200 mg administered subcutaneously every 4 weeks for subjects  $\geq 40$  kg or 100 mg for subjects 20 to  $< 40$  kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

|                       |   |
|-----------------------|---|
| Reporting group title | Certolizumab pegol: high-dose group (weight adjusted) |
|-----------------------|---|

Reporting group description:

400 mg administered subcutaneously every 4 weeks for subjects  $\geq 40$  kg or 200 mg for subjects 20 to  $< 40$  kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

| Reporting group values                | Certolizumab pegol:<br>low-dose group<br>(weight adjusted) | Certolizumab pegol:<br>high-dose group<br>(weight adjusted) | Total |
|---------------------------------------|--|---|-------|
| Number of subjects                    | 4  | 12  | 16    |
| Age categorical<br>Units: Subjects    |  |   |       |
| $\leq 18$ years                       | 4  | 11  | 15    |
| Between 18 and 65 years               | 0  | 1   | 1     |
| $\geq 65$ years                       | 0  | 0   | 0     |
| Age continuous<br>Units: years        |  |   |       |
| arithmetic mean                       | 13.5   | 13.9  |       |
| standard deviation                    | $\pm 2.4$  | $\pm 2.9$   | -     |
| Gender categorical<br>Units: Subjects |  |   |       |
| Female                                | 2  | 6   | 8     |
| Male                                  | 2  | 6   | 8     |

## End points

### End points reporting groups

|  |   |
|--|---|
| Reporting group title  | Certolizumab pegol: low-dose group (weight adjusted)          |
| Reporting group description:<br>200 mg administered subcutaneously every 4 weeks for subjects $\geq 40$ kg or 100 mg for subjects 20 to $< 40$ kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.   |   |
| Reporting group title  | Certolizumab pegol: high-dose group (weight adjusted)         |
| Reporting group description:<br>400 mg administered subcutaneously every 4 weeks for subjects $\geq 40$ kg or 200 mg for subjects 20 to $< 40$ kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.   |   |
| Subject analysis set title   | Certolizumab pegol: low-dose group (weight adjusted) – (SS)   |
| Subject analysis set type  | Safety analysis   |
| Subject analysis set description:<br>200 mg administered subcutaneously every 4 weeks for subjects $\geq 40$ kg or 100 mg for subjects 20 to $< 40$ kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.  |   |
| Subject analysis set title   | Certolizumab pegol: high-dose group (weight adjusted) – (SS)  |
| Subject analysis set type  | Safety analysis   |
| Subject analysis set description:<br>400 mg administered subcutaneously every 4 weeks for subjects $\geq 40$ kg or 200 mg for subjects 20 to $< 40$ kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.  |   |
| Subject analysis set title   | Certolizumab pegol: Re-Induction group – (SS)                 |
| Subject analysis set type  | Safety analysis   |
| Subject analysis set description:<br>If a subject had not been previously reinduced in C87035, the subject is eligible for 1 reinduction due to loss of response in CR0012. Reinduction Week 0 (first reinduction dose) is followed by Reinduction Week 2 (second dose, 2 weeks after first dose), and Reinduction Week 4 (third dose, 2 weeks after second dose). The reinduction dose was adjusted to the subject's weight: 400 mg for subjects $\geq 40$ kg or 200 mg for subjects 20 to $< 40$ kg subcutaneously Q2W for a total of 3 doses. After reinduction was complete participants continued dosing with CZP administered subcutaneously Q4W as 400 mg for subjects $\geq 40$ kg or 200mg for subjects 20 to $< 40$ kg, regardless of the subject's previous randomized dose group). Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study. |   |
| Subject analysis set title   | Certolizumab pegol: low-dose group (weight adjusted) – (ITT)  |
| Subject analysis set type  | Intention-to-treat  |
| Subject analysis set description:<br>200 mg administered subcutaneously every 4 weeks for subjects $\geq 40$ kg or 100 mg for subjects 20 to $< 40$ kg. Part of the Intention-to-Treat (ITT) Population included all subjects irrespective of any protocol deviations who received at least 1 injection of the study treatment and who had at least 1 efficacy measurement after the first injection of this study.  |   |
| Subject analysis set title   | Certolizumab pegol: high-dose group (weight adjusted) – (ITT) |
| Subject analysis set type  | Intention-to-treat  |
| Subject analysis set description:<br>400 mg administered subcutaneously every 4 weeks for subjects $\geq 40$ kg or 200 mg for subjects 20 to $< 40$ kg. Part of the Intention-to-Treat (ITT) Population included all subjects irrespective of any protocol deviations who received at least 1 injection of the study treatment and who had at least 1 efficacy measurement after the first injection of this study.  |   |

### Primary: Number of subjects reporting at least one Treatment-Emergent Adverse Event (TEAE) during study treatment (up to 303 weeks)

|                 |   |
|-----------------|---|
| End point title | Number of subjects reporting at least one Treatment-Emergent Adverse Event (TEAE) during study treatment (up to 303 weeks) <sup>[1]</sup> |
|-----------------|---|

End point description:

Treatment-Emergent Adverse Events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During study treatment (up to 303 weeks)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized as descriptive statistics only.

| End point values            | Certolizumab pegol: low-dose group (weight adjusted) – (SS) | Certolizumab pegol: high-dose group (weight adjusted) – (SS) | Certolizumab pegol: Re-Induction group – (SS) |  |
|-----------------------------|---|--|---|--|
| Subject group type          | Subject analysis set  | Subject analysis set   | Subject analysis set                          |  |
| Number of subjects analysed | 4   | 10   | 2   |  |
| Units: Participants         |   |  |   |  |
| Subjects                    | 2   | 6  | 2   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects discontinuing treatment due to a Treatment-Emergent Adverse Event (TEAE)

|                 |   |
|-----------------|---|
| End point title | Number of subjects discontinuing treatment due to a Treatment-Emergent Adverse Event (TEAE) |
|-----------------|---|

End point description:

Treatment-Emergent Adverse Events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During study treatment (up to 303 weeks)

| End point values            | Certolizumab pegol: low-dose group (weight adjusted) – (SS) | Certolizumab pegol: high-dose group (weight adjusted) – (SS) | Certolizumab pegol: Re-Induction group – (SS) |  |
|-----------------------------|---|--|---|--|
| Subject group type          | Subject analysis set  | Subject analysis set   | Subject analysis set                          |  |
| Number of subjects analysed | 4   | 10   | 2   |  |
| Units: Participants         |   |  |   |  |
| Subjects                    | 0   | 2  | 0   |  |



## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects who develop anti-nuclear antibodies during the study

|                 |   |
|-----------------|---|
| End point title | Number of subjects who develop anti-nuclear antibodies during the study |
|-----------------|---|

End point description:

Anti-nuclear antibodies (ANA) are autoantibodies. ANA titers will be determined every 12 weeks starting at Week 14, and at the Completion/Early Termination and Safety Follow-Up (SFU) Visits.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At the time of completion or termination visit (up to 298 weeks)

| End point values            | Certolizumab pegol: low-dose group (weight adjusted) – (ITT) | Certolizumab pegol: high-dose group (weight adjusted) – (ITT) |  |  |
|-----------------------------|--|---|--|--|
| Subject group type          | Subject analysis set   | Subject analysis set  |  |  |
| Number of subjects analysed | 3  | 10  |  |  |
| Units: Participants         |  |   |  |  |
| Subjects                    | 0  | 3   |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects who develop double-stranded deoxyribonucleic acid (dsDNA) antibodies during the study

|                 |  |
|-----------------|--|
| End point title | Number of subjects who develop double-stranded deoxyribonucleic acid (dsDNA) antibodies during the study |
|-----------------|--|

End point description:

Anti-dsDNA are autoantibodies. Anti-dsDNA titers will be determined every 12 weeks starting at Week 14, and at the Completion/Early Termination and Safety Follow-Up (SFU) Visits.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At the time of completion or termination visit (up to 298 weeks)

| <b>End point values</b>     | Certolizumab<br>pegol: low-<br>dose group<br>(weight<br>adjusted) –<br>(ITT) | Certolizumab<br>pegol: high-<br>dose group<br>(weight<br>adjusted) –<br>(ITT) |  |  |
|-----------------------------|--|---|--|--|
| Subject group type          | Subject analysis set   | Subject analysis set  |  |  |
| Number of subjects analysed | 3  | 10  |  |  |
| Units: Participants         |  |   |  |  |
| Subjects                    | 0  | 0   |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects in clinical remission

|   |  |
|---|--|
| End point title   | Percentage of subjects in clinical remission |
| End point description:<br>Percentage of subjects in clinical remission (clinical remission is defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score $\leq 10$ ) |  |
| End point type  | Secondary                                    |
| End point timeframe:<br>At the time of completion or termination visit (up to 298 weeks)  |  |

| <b>End point values</b>           | Certolizumab<br>pegol: low-<br>dose group<br>(weight<br>adjusted) –<br>(ITT) | Certolizumab<br>pegol: high-<br>dose group<br>(weight<br>adjusted) –<br>(ITT) |  |  |
|-----------------------------------|--|---|--|--|
| Subject group type                | Subject analysis set   | Subject analysis set  |  |  |
| Number of subjects analysed       | 3  | 9   |  |  |
| Units: Percentage of participants |  |   |  |  |
| number (not applicable)           |  |   |  |  |
| percentage of subjects            | 100  | 44.4  |  |  |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

During study treatment (up to 303 weeks)

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 20.1 |
|--------------------|------|

### Reporting groups

|                       |   |
|-----------------------|---|
| Reporting group title | Certolizumab pegol: low-dose group (weight adjusted) – (SS) |
|-----------------------|---|

Reporting group description:

200 mg administered subcutaneously every 4 weeks for subjects  $\geq 40$  kg or 100 mg for subjects 20 to  $< 40$  kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

|                       |   |
|-----------------------|---|
| Reporting group title | Certolizumab pegol: Re-Induction group – (SS) |
|-----------------------|---|

Reporting group description:

If a subject had not been previously reinduced in C87035, the subject is eligible for 1 reinduction due to loss of response in CR0012. Reinduction Week 0 (first reinduction dose) is followed by Reinduction Week 2 (second dose, 2 weeks after first dose), and Reinduction Week 4 (third dose, 2 weeks after second dose). The reinduction dose was adjusted to the subject's weight: 400 mg for subjects  $\geq 40$  kg or 200 mg for subjects 20 to  $< 40$  kg subcutaneously Q2W for a total of 3 doses. After reinduction was complete participants continued dosing with CZP administered subcutaneously Q4W as 400 mg for subjects  $\geq 40$  kg or 200mg for subjects 20 to  $< 40$  kg, regardless of the subject's previous randomized dose group). Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

|                       |  |
|-----------------------|--|
| Reporting group title | Certolizumab pegol: high-dose group (weight adjusted) – (SS) |
|-----------------------|--|

Reporting group description:

400 mg administered subcutaneously every 4 weeks for subjects  $\geq 40$  kg or 200 mg for subjects 20 to  $< 40$  kg. Part of the Safety Set (SS) included all subjects enrolled, who received at least 1 injection of study treatment in this study.

| <b>Serious adverse events</b>                     | Certolizumab pegol:<br>low-dose group<br>(weight adjusted) –<br>(SS) | Certolizumab pegol:<br>Re-Induction group<br>– (SS) | Certolizumab pegol:<br>high-dose group<br>(weight adjusted) –<br>(SS) |
|---|--|---|---|
| Total subjects affected by serious adverse events |  |   |   |
| subjects affected / exposed                       | 0 / 4 (0.00%)  | 1 / 2 (50.00%)                                      | 4 / 10 (40.00%)   |
| number of deaths (all causes)                     | 0  | 0   | 0   |
| number of deaths resulting from adverse events    | 0  | 0   | 0   |
| Gastrointestinal disorders                        |  |   |   |
| Crohn's disease                                   |  |   |   |
| subjects affected / exposed                       | 0 / 4 (0.00%)  | 1 / 2 (50.00%)                                      | 1 / 10 (10.00%)   |
| occurrences causally related to treatment / all   | 0 / 0  | 0 / 1   | 1 / 1   |
| deaths causally related to treatment / all        | 0 / 0  | 0 / 0   | 0 / 0   |
| Small intestinal obstruction                      |  |   |   |

|   |               |                |                 |
|---|---------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0           |
| Psychiatric disorders                           |               |                |                 |
| Suicide attempt                                 |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0           |
| Infections and infestations                     |               |                |                 |
| Anal abscess                                    |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 1 / 2 (50.00%) | 0 / 10 (0.00%)  |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0           |
| Gastritis viral                                 |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0           |
| Pancreatitis viral                              |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0           |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | Certolizumab pegol:<br>low-dose group<br>(weight adjusted) –<br>(SS) | Certolizumab pegol:<br>Re-Induction group<br>– (SS) | Certolizumab pegol:<br>high-dose group<br>(weight adjusted) –<br>(SS) |
|---|--|---|---|
| Total subjects affected by non-serious adverse events |  |   |   |
| subjects affected / exposed                           | 2 / 4 (50.00%)   | 2 / 2 (100.00%)                                     | 5 / 10 (50.00%)   |
| Investigations  |  |   |   |
| C-reactive protein increased                          |  |   |   |
| subjects affected / exposed                           | 0 / 4 (0.00%)  | 1 / 2 (50.00%)                                      | 0 / 10 (0.00%)  |
| occurrences (all)                                     | 0  | 1   | 0   |
| Haemoglobin decreased                                 |  |   |   |
| subjects affected / exposed                           | 0 / 4 (0.00%)  | 1 / 2 (50.00%)                                      | 0 / 10 (0.00%)  |
| occurrences (all)                                     | 0  | 1   | 0   |

|  |                     |                     |                      |
|--|---------------------|---------------------|----------------------|
| Ultrasound abdomen<br>subjects affected / exposed<br>occurrences (all)   | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| Vitamin D decreased<br>subjects affected / exposed<br>occurrences (all)  | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| Injury, poisoning and procedural complications<br>Abdominal injury<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0  | 1 / 2 (50.00%)<br>1 | 0 / 10 (0.00%)<br>0  |
| Procedural pain<br>subjects affected / exposed<br>occurrences (all)  | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| Nervous system disorders<br>Dizziness<br>subjects affected / exposed<br>occurrences (all)                              | 1 / 4 (25.00%)<br>1 | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>2 |
| Headache<br>subjects affected / exposed<br>occurrences (all)   | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>3 |
| Blood and lymphatic system disorders<br>Iron deficiency anaemia<br>subjects affected / exposed<br>occurrences (all)    | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| General disorders and administration site conditions<br>Chest pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| Chills<br>subjects affected / exposed<br>occurrences (all)   | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| Fatigue<br>subjects affected / exposed<br>occurrences (all)  | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| Pain   |                     |                     |                      |

|                             |                |                |                 |
|-----------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 4 (0.00%)  | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)           | 0              | 0              | 2               |
| Pyrexia                     |                |                |                 |
| subjects affected / exposed | 0 / 4 (0.00%)  | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)           | 0              | 0              | 1               |
| Gastrointestinal disorders  |                |                |                 |
| Abdominal pain upper        |                |                |                 |
| subjects affected / exposed | 0 / 4 (0.00%)  | 0 / 2 (0.00%)  | 4 / 10 (40.00%) |
| occurrences (all)           | 0              | 0              | 5               |
| Nausea                      |                |                |                 |
| subjects affected / exposed | 0 / 4 (0.00%)  | 0 / 2 (0.00%)  | 2 / 10 (20.00%) |
| occurrences (all)           | 0              | 0              | 2               |
| Stomatitis                  |                |                |                 |
| subjects affected / exposed | 0 / 4 (0.00%)  | 1 / 2 (50.00%) | 1 / 10 (10.00%) |
| occurrences (all)           | 0              | 1              | 1               |
| Abdominal tenderness        |                |                |                 |
| subjects affected / exposed | 0 / 4 (0.00%)  | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)           | 0              | 0              | 1               |
| Anal fissure                |                |                |                 |
| subjects affected / exposed | 0 / 4 (0.00%)  | 1 / 2 (50.00%) | 0 / 10 (0.00%)  |
| occurrences (all)           | 0              | 1              | 0               |
| Crohn's disease             |                |                |                 |
| subjects affected / exposed | 0 / 4 (0.00%)  | 1 / 2 (50.00%) | 0 / 10 (0.00%)  |
| occurrences (all)           | 0              | 1              | 0               |
| Diarrhoea                   |                |                |                 |
| subjects affected / exposed | 0 / 4 (0.00%)  | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)           | 0              | 0              | 1               |
| Dyspepsia                   |                |                |                 |
| subjects affected / exposed | 0 / 4 (0.00%)  | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)           | 0              | 0              | 1               |
| Gastritis                   |                |                |                 |
| subjects affected / exposed | 0 / 4 (0.00%)  | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)           | 0              | 0              | 1               |
| Oesophagitis                |                |                |                 |
| subjects affected / exposed | 1 / 4 (25.00%) | 0 / 2 (0.00%)  | 0 / 10 (0.00%)  |
| occurrences (all)           | 1              | 0              | 0               |

|  |                     |                     |                      |
|--|---------------------|---------------------|----------------------|
| Tooth impacted<br>subjects affected / exposed<br>occurrences (all)   | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)   | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>2 |
| Respiratory, thoracic and mediastinal disorders<br>Dysmenorrhoea<br>subjects affected / exposed<br>occurrences (all) | 1 / 4 (25.00%)<br>1 | 0 / 2 (0.00%)<br>0  | 0 / 10 (0.00%)<br>0  |
| Cough<br>subjects affected / exposed<br>occurrences (all)  | 1 / 4 (25.00%)<br>1 | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>6 |
| Asthma exercise induced<br>subjects affected / exposed<br>occurrences (all)  | 1 / 4 (25.00%)<br>1 | 0 / 2 (0.00%)<br>0  | 0 / 10 (0.00%)<br>0  |
| Epistaxis<br>subjects affected / exposed<br>occurrences (all)  | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| Nasal congestion<br>subjects affected / exposed<br>occurrences (all)   | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| Oropharyngeal pain<br>subjects affected / exposed<br>occurrences (all)   | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>1 |
| Rhinorrhoea<br>subjects affected / exposed<br>occurrences (all)  | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>2 |
| Skin and subcutaneous tissue disorders<br>Ingrowing nail<br>subjects affected / exposed<br>occurrences (all)         | 0 / 4 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  | 1 / 10 (10.00%)<br>2 |
| Psychiatric disorders<br>Enuresis<br>subjects affected / exposed<br>occurrences (all)                                | 0 / 4 (0.00%)<br>0  | 1 / 2 (50.00%)<br>1 | 0 / 10 (0.00%)<br>0  |

|   |               |                |                 |
|---|---------------|----------------|-----------------|
| Musculoskeletal and connective tissue disorders |               |                |                 |
| Pain in extremity                               |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 2 / 10 (20.00%) |
| occurrences (all)                               | 0             | 0              | 2               |
| Arthralgia                                      |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)                               | 0             | 0              | 5               |
| Back pain                                       |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)                               | 0             | 0              | 1               |
| Joint stiffness                                 |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)                               | 0             | 0              | 2               |
| Infections and infestations                     |               |                |                 |
| Nasopharyngitis                                 |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 2 / 10 (20.00%) |
| occurrences (all)                               | 0             | 0              | 2               |
| Ear infection                                   |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)                               | 0             | 0              | 2               |
| Furuncle  |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 1 / 2 (50.00%) | 0 / 10 (0.00%)  |
| occurrences (all)                               | 0             | 1              | 0               |
| Localised infection                             |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)                               | 0             | 0              | 1               |
| Pharyngitis streptococcal                       |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)                               | 0             | 0              | 1               |
| Upper respiratory tract infection               |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)                               | 0             | 0              | 1               |
| Metabolism and nutrition disorders              |               |                |                 |
| Vitamin D deficiency                            |               |                |                 |
| subjects affected / exposed                     | 0 / 4 (0.00%) | 0 / 2 (0.00%)  | 1 / 10 (10.00%) |
| occurrences (all)                               | 0             | 0              | 2               |





## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date         | Amendment   |
|--------------|---|
| 29 June 2010 | Amendment 1: <ul style="list-style-type: none"><li>- The telephone numbers for reporting serious adverse events (SAEs) during business hours or outside business hours have been indicated.</li><li>- The inclusion and exclusion criteria were simplified to include subject who completed C87035.</li><li>- Pregnancy due to oral contraceptive failure is not considered an SAE; the change was made to comply with Sponsor SAE reporting procedures.</li><li>- An additional example of an important medical event relevant to subjects with Crohn's disease (CD) (infections that require treatment with parental antibiotics) was provided.</li><li>- An inconsistency in Visit 2 vital signs compared to Schedule of Study Assessments was corrected in Section 9.6.7.</li></ul>   |
| 08 May 2012  | Amendment 2: <ul style="list-style-type: none"><li>- Following a meeting with the Food and Drug Administration (FDA) in Apr 2012, the decision was made to stop C87035 after determining it was inadequate to address the efficacy of certolizumab pegol (CZP) for labeling in pediatric subjects.</li><li>- CR0012 was amended to allow subjects ongoing in C87035 to enter CR0012 without having completed C87035, and for treatment in CR0012 to be continued until a subject reached age of 18 years or CZP is approved for use in the US by pediatric subjects with Crohn's disease (CD).</li><li>- Additional updates were made to reflect the current UCB contacts, regulatory status of CZP, subject exposure, and to comply with the updated UCB definition of adverse events (AEs) of interest.</li><li>- The format and style of the document was changed to comply with UCBs new document-authoring software; these changes are not specifically noted.</li></ul> |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported